Quarterly Earnings

BGMS is pivoting from fire safety via a reverse merger with Future NRG. The deal gives NRG shareholders 99% control, creating a new environmental services giant.

Marchex's standalone revenue is falling, but its major AI acquisition, Archenia, is already boosting its outlook. Can this strategic pivot deliver lasting value?

After a rocky Q1, Ellington Credit Company's active strategy in the volatile CLO market paid off, delivering strong returns and a blueprint for resilience.

With pivotal data due in September, Connect Biopharma's rademikibart could redefine acute asthma and COPD care. Can it navigate this clinical tightrope?

Despite grim Q2 financials, Perma-Fix secures a key role in the massive Hanford cleanup, a multi-billion dollar gamble that could define its future.

Liftoff Mobile reported a net loss, but a look past the IPO-related accounting reveals a company firing on all cylinders, with its AI platform driving record revenue.

Starlight's Western Canada fund posted a net loss, but a 102% jump in key cash flow metrics reveals a booming operation fueled by a major acquisition.

Journey Medical posts a stellar 23% revenue jump, nearing profitability. But beyond the headlines, a crucial SEC filing reveals a complex financial reality.

A 30% revenue dip masks a strategic pivot at OptimizeRx. Inside the numbers, a story of disciplined debt management and a bold bet on AI innovation emerges.

With pivotal lung cancer data imminent, ArriVent BioPharma juggles a high-risk, high-reward strategy, betting its future on a novel drug and a new wave of ‘smart bomb’ therapies.

FGI Industries defied market chaos with a stunning return to profitability, driven by disciplined cost control and a savvy global sourcing strategy.

The private credit firm posted a strong quarter with a rising NAV, but the real story is the recent acquisition of its advisor by asset giant Ridgepost Capital.

Identiv sells its core IoT business, pivoting to a high-risk, high-reward strategy in Physical AI and Compliance SaaS. A deep dive into the deal.

With an October FDA deadline for its lead drug, INOVIO walks a financial tightrope, betting its future on a first-in-class treatment and a broader DNA platform.

Beasley Broadcast Group's massive Q2 profit stems from a debt maneuver, not revenue. A deep dive into its digital pivot and cost cuts reveals its true test.

Minerva Foods posts record-breaking revenue and deftly manages its debt, yet its stock falters. A deep dive into a strategy built for long-term resilience.

With revenue guidance soaring past $900M, Spectral Capital looks like a runaway success. A closer look reveals a complex picture of non-cash gains and high-stakes gambles.

Beyond a 23% profit surge, ILCO's latest results reveal a blueprint for resilience through strategic IPOs, dividends, and a diversified portfolio.

Neonode's Q2 report shows shrinking revenue and widening losses, but a massive jump in MultiSensing® license sales points to a deliberate, high-stakes bet on the automotive sector.

As HSDT prepares to report Q2 results, investors are watching closely. Is its unique strategy of tying shareholder value directly to the Solana ecosystem paying off?